s0099965
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.400
- COMPLEMENT+0.400
- E2F_TARGETS+0.400
- G2M_CHECKPOINT+0.400
- INFLAMMATORY_RESPONSE+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
- IL6_JAK_STAT3_SIGNALING+0.300
- TGF_BETA_SIGNALING+0.300
Top 10 suppressed
- ADIPOGENESIS-0.300
- NOTCH_SIGNALING-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- BILE_ACID_METABOLISM-0.200
- GLYCOLYSIS-0.200
- HEDGEHOG_SIGNALING-0.200
- HYPOXIA-0.200
- MYOGENESIS-0.200
- PANCREAS_BETA_CELLS-0.200
- WNT_BETA_CATENIN_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s0112313 | — | — | 0.861 |
| 2 | MNG766 | — | — | 0.827 |
| 3 | ERR2278877 | — | — | 0.797 |
| 4 | 6d7694d5-8582-466f-8072-df47dc10d780 | — | — | 0.797 |
| 5 | 346fe4c0-2ea0-45b4-8863-b0f9e7756ad6 | — | — | 0.795 |
| 6 | ERR2278874 | — | — | 0.793 |
| 7 | TCGA-CR-7373-01A-11R-2016-07 | — | — | 0.790 |
| 8 | TCGA-AO-A128-01A-11R-A10J-07 | — | D | 0.788 |
| 9 | 57c4a274-647d-4499-a8f8-a79e446ab4a7 | — | — | 0.787 |
| 10 | TCGA-83-5908-01A-21R-2287-07 | — | cohortA1 | 0.786 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |